Original article

Impact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study

Blanca Olivia Murillo Ortiz [a],*, Joel Ramírez Emiliano [b], Marcos Javier Romero Vázquez [a],
Lauro Fabián Amador Medina [a], Sandra Martínez Garza [a],
Edna Montserrat Ramos Rodríguez [c]

[a] *Clinical Epidemiology Research Unit, OOAD Guanajuato, Mexican Institute of Social Security, León, Guanajuato, Mexico*
[b] *Department of Medical Sciences, Health Sciences Division, University of Guanajuato, León, Guanajuato, Mexico*
[c] *Department of Hemodialysis, Hospital General Regional No. 58, Mexican Institute of Social Security, León, Guanajuato, Mexico*

ARTICLE INFO

ABSTRACT

Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis.

Objective: To investigate the impact of iron chelation on telomere length, oxidative stress, and ferritin levels in patients undergoing hemodialysis.

Methods: This is an open-label study, with a control group of patients undergoing hemodialysis, who will receive treatment with deferasirox 15 mg/kg/day for 6 months for iron chelation. Telomere length was measured using real-time PCR. Serum ferritin levels and oxidation markers were evaluated. To evaluate the pharmacokinetics and safety of deferasirox, plasma concentrations were analyzed by HPLC.

Results: Fifty-four patients were included to receive deferasirox, and a control group of 50 patients. Significant differences were observed in serum ferritin levels ($p < 0.0001$), TBARS (thiobarbituric acid reactive substances) ($p < 0.01$). Telomere length had a significant increase after chelation ($p < 0.001$). The serum deferasirox concentration at zero time at 48 h was maintained within a range of 2.67–23.78 mmol/L.

Conclusions: Our results demonstrate that iron chelation in hemodialysis patients significantly reduces ferritin and TBARS, resulting in an increase in telomere length. Deferasirox proves to be beneficial for patients with iron overload undergoing hemodialysis.

* *Corresponding author.*
E-mail address: bomo907@hotmail.com (B.O. Murillo Ortiz).

Impacto de la quelación de hierro con deferasirox en la longitud de los telómeros y estrés oxidativo en pacientes en hemodiálisis: un estudio aleatorizado

RESUMEN

Palabras clave:

Sobrecarga de hierro

Quelación

Estrés oxidativo

Largo del telómero

Hemodiálisis

Antecedentes: Estudios recientes han demostrado la eficacia, seguridad y tolerabilidad del deferasirox en pacientes en diálisis peritoneal, sin embargo, su efecto no ha sido estudiado en pacientes sometidos a hemodiálisis.

Objetivo: Investigar el impacto de la quelación del hierro sobre la longitud de los telómeros, el estrés oxidativo y los niveles de ferritina en pacientes sometidos a hemodiálisis.

Método: Se trata de un estudio abierto, con un grupo control de pacientes en hemodiálisis, que recibieron tratamiento con deferasirox 15 mg/kg/día durante 6 meses para la quelación del hierro. La longitud de los telómeros se midió mediante PCR en tiempo real. Se evaluaron los niveles séricos de ferritina y los marcadores de oxidación. Para evaluar la farmacocinética y la seguridad del deferasirox, se analizaron las concentraciones plasmáticas mediante HPLC.

Resultados: Se incluyeron 54 pacientes para recibir deferasirox, y un grupo control de 50 pacientes. Se observaron diferencias significativas en los niveles séricos de ferritina ($p < 0,0001$), TBARS (sustancias reactivas al ácido tiobarbitúrico) ($p < 0,01$). La longitud de los telómeros aumentó significativamente tras la quelación ($p < 0,001$). La concentración sérica de deferasirox a tiempo cero a las 48 h se mantuvo dentro de un rango de 2,67 a 23,78 mmol/L.

Conclusiones: Nuestros resultados demuestran que la quelación del hierro en pacientes en hemodiálisis reduce significativamente la ferritina y el TBARS, lo que se traduce en un aumento de la longitud de los telómeros. El deferasirox demuestra ser beneficioso para los pacientes con sobrecarga de hierro sometidos a hemodiálisis.

Introduction

Anemia in chronic kidney disease shares characteristics with anemia in other chronic diseases, although the decrease in erythropoietin production mediated by renal failure and the antiproliferative effects of accumulated uremic toxins contribute significantly.[1]

Ferritin is the iron storage protein. While large amounts of ferritin are present in iron-storing tissues such as the liver and bone marrow, only tiny amounts are present in the serum. This makes serum ferritin concentration a valuable indicator of the stored iron status. However, ferritin acts as an acute-phase reactant, leading to increased serum concentrations during acute inflammatory processes.[2] Iron homeostasis dependents on regulatory feedback mechanisms.[3]

Stored iron levels in healthy subjects range from approximately 800–1200 mg. Iron overload is a common complication in patients with chronic renal failure undergoing dialysis. The frequent need for red cell transfusions to treat symptomatic anemia. The repetitive use of parenteral iron with or without red cell transfusions, also contributes to iron overload.[4] However, excess iron can generate highly toxic free radicals that cause oxidative damage to almost all cellular components, including DNA, membranes, and proteins.[5,6]

Currently, iron overload and the use of iron therapy are not well established in patients with chronic kidney disease. In the latest KDIGO update, a serum ferritin ≥500 ng/mL and transferrin saturation (TSAT) ≥30 are recommended as benchmarks for stopping iron therapy.[7] However, some guidelines even suggest serum ferritin values of 500–800 ng/mL. MRI is now the gold standard for estimation and monitoring of iron stores, although it is not yet widely accepted due to its limited availability in resource-limited countries.[8] Furthermore, it is difficult to determine whether iron detected in the liver is deposited within parenchymal hepatocytes or stored safely within reticuloendothelial cells. Therefore, serum ferritin and TSAT remain the values considered for iron overload, as noted in the study by Ghoti et al. where hemodialysis patients with ferritin >1000 ng/dL, who had increased iron deposition in the liver and spleen, were studied.[9] Therefore, in our study, a cut-off point of ferritin >1000 ng/dL was considered as a reference.

Postmortem studies have detected iron in atherosclerotic lesions compared to arteries of healthy patients.[10,11] Additionally, the Bruneck study indicates that serum ferritin and LDL cholesterol have synergistic effects associated with the progression of carotid atherosclerosis, suggesting that iron promotes lipid peroxidation.[12]

Patients with end stage renal disease have a markedly increased risk of presenting cardiovascular complications compared to the general population.[13] In the general population, it has been associated with basal concentrations of ferritin and transferrin with multiple abnormalities of metabolic syndrome, primarily with hyperinsulinemia and a high insulin resistance index (HOMA-IR).[14]

Interestingly, the recently published Pivotal trial,[15] non-inferiority was demonstrated whit a slight superiority related to fewer cardiovascular events fatal and no fatal myocardial infarction or hospitalizations for cardiac failure. Also confirmed that maintenance iron therapy is better than an iron loading strategy for sparing recombinant erythropoiesis stimulating agents.

A published study found that elevated levels of ferritin, even those much lower than those that are not normally regarded as high, are associated with a decreased probability of deterioration of cardiovascular fitness, primarily in young adults.[16] Although there is evidence that the total iron in the body is related to the development of various disease, however, there is limited scientific evidence regarding what occurs at the DNA level.

Telomeres are considered indicators of biological age and are specialized structures at the ends of human chromosomes. Early studies showed the essential role of telomeres in the integrity of chromosomes. These nucleoprotein hoods or caps are conserved by the telomerase enzyme.[17]

Human studies have correlated the shortening of telomeres in peripheral blood leukocytes with high mortality rates.[18] A study of centenarians and their descendants found a positive relationship between telomere length and longevity.[19,20]

Telomere shortening increases with the progressive exposure to different factors of inflammation and oxidative stress that have a direct effect on the progressive loss of telomere length.[21] Chronic oxidative stress accelerates cellular aging, renal dysfunction is associated with shorter telomere length in heart failure.[22] Moreover, telomere shortening has been associated with hypertension, endothelial dysfunction, atherosclerosis, and cardiovascular mortality.[23] Recent evidence shows that there is a strong association between telomere shortening and moderate chronic kidney disease and increased risk of death.[24]

In patients with type 2 diabetes mellitus telomeric length is shorter than healthy subjects of the same age.[25] An association with microalbuminuria and albumin excretion has been reported. The evolution time increases oxidative stress, inflammation and loss of telomere length.[26]

During the aging process, renal function decreases, leading to a noticeable reduction in the glomerular flow rate, along with an increase in vascular resistance and loss of 20–25% of the renal mass. Research has shown that telomere shortening initially occurs in cells of the cortex rather than in the renal medulla.[27] The increased oxidative stress caused by iron oversaturation may contribute to this telomere shortening, potentially leading to renal diseases such as glomerulosclerosis and preventing renal regeneration. Measuring telomere length will provide us with evidence of aging that occurs as a result of oxidative stress due to the high iron content stored within the body.[28]

Deferasirox (Exjade, ICL670) is a potent and specific iron chelator administered orally, approved as a first-line therapy in patients with chronic iron overload in transfusion-dependent anemias. The recommended starting dose is 20 mg/kg/day, with a maximum recommended dose of 40 mg/kg/day.[29,30]

Pharmacodynamic effects tested in the metabolic balance of iron have shown that deferasirox at doses of 10, 20, and 40 mg/kg/day is capable of inducing a net iron excretion of 0.119, 0.329 and 0.445 mg/Fe/kg/day with clinical relevance in the range of 0.1–0.5 mg/kg/day. In addition to achieving a reduction in plasma iron levels, deferasirox has been shown to reduce liver iron concentration.[31–33]

The background outlined above suggests that, due to iron overload, oxidative stress, which affects all cells and causes accelerated telomere shortening increases. In patients with chronic renal failure at the bone marrow level, replicative power is affected in erythroid progenitor cells due to telomere length shortening. Therefore, the use of iron chelation therapy is important for this patient population, as elevated ferritin levels will continue to increase with the constant use of intravenous or oral iron supplement, as well as multiple red blood cells transfusions.

The general objective of this study was to identify the effect of iron chelation with deferasirox on telomere length and oxidative stress levels in patients undergoing hemodialysis.

Methods

This is a randomized, single-arm, open-label simple arm and controls study to determine the effect of iron chelation with deferasirox on telomere length and oxidative stress markers in patients undergoing renal replacement therapy with hemodialysis and a glomerular filtration rate $<15 \, \text{mL/min}/1.73 \, \text{m}^2$. The study includes patients ≥ 18 years, with a history of being multitransfused and having received oral and/or intravenous iron replacement therapy, with ferritin levels greater than 1000 ng/mL that require iron chelation therapy, with leukocytes >5000/mL and platelets >150,000/mL, with liver enzymes <2.0 times normal levels, and total bilirubin <1.5, coming from the Unidad Médica de Alta Especialidad No. 1 Bajío.

Exclusion criteria

Patients with moderate to severe smoking, with active alcoholism at the time of the study, who have already received a kidney transplant, who present uncontrolled systemic arterial hypertension, systemic cardiovascular disease, hepatic impairment (ALT > 300 U/L). Patients with a history of autoimmune diseases (lupus erythematosus, focal segmental glomerulosclerosis), with any surgical or medical condition that prevents the correct absorption of Exjade. Female patients in pregnancy and/or lactation, were not included.

All the patients were invited to participate, and informed consent was obtained; they signed written informed consent to understand the effects of treatment with deferasirox (an iron chelator). The study complies with the Consolidated Standards of Reporting Trials,[34] and the Helsinki Declaration and was approved by the Institutional Ethical Committee of the Mexican Institute of Social Security (IMSS R-2015-785-125).

Patients of both genders were included. Two groups of patients undergoing renal replacement therapy with hemodialysis, who had a history of iron overload and were

Table 1 – Characteristics demographic, clinical and therapeutic.			
Variable	Group treated deferasirox $n = 54$	Group control $n = 50$	*p* value*
Age (years)	44 ± 16.29	46 ± 11.26	≥ 0.05
Male, *n* (%)	39 (72.22)	35 (70)	≥ 0.05
Hypertension (%)	74	73	≥ 0.05
Diabetes (%)	18.5	19.0	≥ 0.05
Duration of hemodialysis (months)	40.87 ± 41.65	40.43 ± 40.75	≥ 0.05
Current previous IV iron therapy (%)	98	97	≥ 0.05
Erythropoietin-stimulating agents UI/per week	$24,000 \pm 4258$	$24,000 \pm 2783$	≥ 0.05
Residual renal function <100 mL/24 h (%)	11.0	11.0	≥ 0.05
* Wilcoxon signed-rank test.			

not currently undergoing intravenous iron therapy, were randomly selected to receive deferasirox or to be part of the control group. They were randomly assigned using a computer-generated list of random numbers, centrally. Patients were evaluated monthly for 6 months of treatment with deferasirox at a dose to 15 mg/kg. Routine biochemical marker tests were performed to assess liver function, and blood counts were observed during all visits to determine if any adverse effects had occurred. Timely reports were made to the national pharmacovigilance center according to NOM-220-SSA1-2012 evaluating the possible need for dose adjustment or discontinuation of treatment.

Serum levels of glucose were determined using the glucose oxidase-peroxidase method (Biosystems, Spain). Creatinine, urea, cholesterol, and triglycerides were estimated using enzymatic methods (STANBIO Laboratory, Boerne, TX, USA). Ferritin levels in plasma were determined with an automated analyzer using dry chemistry technique and reported in units of the IS (ng/mL). Serum TBARS levels were quantified to assess oxidative damage to lipids. To evaluate oxidative damage to oxidized proteins, serum carbonyls were quantified.

DNA samples were extracted from white blood cells. The ratio of telomere repeat copy number to a single gene copy number (T/S) was determined using a modified version of the quantitative real-time PCR telomere assay, as previously described.[20]

Deferasirox was administered orally every day at a dose of 15 mg/kg/day weight, for 3 months. Ferritin levels were evaluated on this date to recalculate the dose. If ferritin levels were below 500 mg, the dose was adjusted to 10 mg/kg for an additional for three more months. Patient monitoring took place during each visit to assess treatment adherence and the presence of adverse events. Biochemical and anthropometric parameters (such as body weight) were monitored to determine whether the dose needed adjustment or if treatment with deferasirox should be continued.

If a patient did not attend their scheduled hemodialysis therapy visit, the principal investigator was alerted to reschedule the visit. If a patient did not present on two consecutive occasions, an investigation was conducted to determine the reason for the absence. This assessment aimed to determine if it was necessary to temporarily discontinue treatment or if some event had occurred that excluded the patient from the study (for example, a fistula infection, or another complication that prevented continued treatment).

Pharmacokinetics and safety of deferasirox

Based on the results of Maker et al.,[33] we proposed to evaluate the pharmacokinetics and safety of deferasirox by HPLC analyzing the plasma concentration in a representative pilot group of four patients. This group was chosen randomly. The dose to be administered is 15 mg/kg per day, as reported in the pilot study. Samples were collected at 2, 4, 6 h after the first dose of deferasirox. At 24 h, just before the second dose of deferasirox, a new sample was taken, and 2 h later corresponding to the serum evaluation at 26 h. At 48 h, the last sample was taken before the administration of oral deferasirox and after hemodialysis.

Statistical analysis

Statistical analysis was performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Descriptive statistics were obtained for continuous variables, and comparisons were made using corresponding non-parametric approaches (Wilcoxon signed-rank test). To analyze the difference in serum concentrations of deferasirox over time, the Mann–Whitney *U* test was used, with *p* <0.05 considered significant.

Results

In the present study, 54 patients were included to receive deferasirox, and a control group of 50 patients was established. The treated group had an average age of 44 ± 16.29 years, 27. 77% were female and 72.22% male. Among them, 74% had systemic arterial hypertension, and 18.5% had type 2 diabetes mellitus. The patients had a history of therapy with intravenous iron dextran at a dose of 100 mg in each hemodialysis session for 3 months, subsequently adjusted according to serum ferritin concentration and TSAT (Table 1).

Five patients did not complete the 6 months of treatment, one male patient presented with catheter dysfunction, so he retired from the study; another male patient changed the modality of replacement therapy to peritoneal dialysis. One female patient received a kidney transplant, and two patients did not have ferritin levels available for the indication of deferasirox. No deaths occurred during the study, there were no serious adverse events (Fig. 1).

Fig. 1 – Flowchart. TBARS: thiobarbituric acid reactive substances; ALT: alanine aminotransferase; AST: aspartate aminotransferase.

At the end of the treatment, significant differences were observed when comparing serum ferritin levels (1239.3 ± 1228.1 ng/mL vs 2093.4 ± 1381.8 ng/mL, $p < 0.0001$), TBARS (24.32 ± 15.91 nmol/mL vs 36.13 ± 20.52 nmol/mL, $p < 0.01$), but not in carbonyls (21.80 ± 7.88 ng/µL vs 24.32 ± 15.91 ng/µL, $p = 0.28$).

The response in hemoglobin (12.47 ± 1.84 vs 10.9 ± 1.4, $p = 0.001$) and hematocrit (38.41 ± 5.86 vs 34.3 ± 4.8, $p < 0.002$) was significantly higher in the group treated with deferasirox when comparing the two groups. However, no significant response was response in leukocytes and platelets ($p > 0.05$). The C-reactive protein showed no changes at the end of the treatment (3.70 ± 2.60 vs 3.55 ± 2.50, $p = 0.76$). Telomere length increased significantly at the end of chelation (5.03 ± 2.15 kb vs. 6.71 ± 2.11 kb, $p = 0.001$), while in the control group no changes were observed (5.43 ± 1.67 kb vs 5.42 ± 2.23 kb, $p = 0.68$). The study variables were compared with the control group as seen in Table 2. Eleven percent of patients in both groups had residual renal function <100 mL/24 h. Creatinine levels decreased considerably in the treated group (8.62 ± 3.66 vs 10.12 ± 1.88, $p = 0.01$). All patients received on average IU of erythropoietin, with a range of (4000–24,000 IU per week).

Plasma levels of deferasirox (mmol/L) were analyzed in four patients. Prior to hemodialysis treatment (zero day), blood samples were taken at time zero (before oral intake of deferasirox). Subsequently deferasirox was orally administered at a dose of 15 mg/kg. Samples were collected, and the average concentration was measured at 2 h (6.50 mmol/L), 4 h (5.11 mmol/L), 6 h (9.24 mmol/L), after this first dose of deferasirox. At 24 h (12.32 mmol/L), just before the second dose of deferasirox, a new sample was taken, and 2 h later corresponding to the serum evaluation at 26 h (10.36 mmol/L). At 48 h (15.08 mmol/L), the last sample was taken before the administration of oral deferasirox and after hemodialysis. Fig. 2 shows the concentrations (mmol/L) determined by HPLC at different times.

Table 2 – Comparison of biochemical markers at baseline and end of treatment.

Variable	Baseline Group treated deferasirox n = 54	Final Group treated deferasirox n = 49	p value*	Baseline Group control n = 50	Final Group control n = 50	p value*	Intergroup p value**
Ferritin (ng/mL)	2093.41 ± 1381.84	1239.36 ± 1228.10	**0.0001**	2003.69 ± 518.73	2578 ± 580.45	**0.001**	**0.001**
Transferrin	146.16 ± 63.26	144.87 ± 48.80	0.69	148.34 ± 53.57	144.87 ± 48.80	0.73	0.86
TSAT %	48.48 ± 29.93	34.37 ± 20.59	**0.006**	43.80 ± 22.70	44.20 ± 21.89	0.92	**0.02**
TBARS (nmol/mL)	36.13 ± 20.52	24.32 ± 15.91	**0.01**	40.45 ± 29.21	50.19 ± 32.62	0.76	**0.01**
Carbonyls (ng/μL)	24.32 ± 15.91	21.80 ± 7.88	0.26	23.67 ± 10.75	22.50 ± 0.85	0.50	0.53
Telomere length (kb)	5.03 ± 2.15	6.71 ± 2.11	**0.001**	5.43 ± 1.67	5.42 ± 2.23	0.68	**0.003**
Hemoglobin (g/dL)	12.22 ± 1.86	12.47 ± 1.84	0.88	12.55 ± 1.38	10.9 ± 1.4	**0.001**	**0.001**
Hematocrit (%)	38.12 ± 5.74	38.41 ± 5.86	0.88	38.43 ± 5.55	34.3 ± 4.8	**0.001**	**0.002**
Platelets (1×10^3)	155.47 ± 50.92	155.67 ± 53.39	0.99	148.54 ± 49.67	152.83 ± 9.87	0.55	0.71
Leukocytes (1×10^3)	5.41 ± 1.57	5.41 ± 1.66	0.65	5.87 ± 1.78	5.38 ± 1.65	0.15	0.92
Creatinine (mg/dL)	11.05 ± 2.98	8.62 ± 3.66	0.29	9.94 ± 2.96	10.12 ± 1.88	0.71	**0.01**
Urea (mg/dL)	106.15 ± 34.94	102.49 ± 42.27	0.76	115.13 ± 38.41	120.9 ± 34.7	0.43	0.01
Glucose (mg/dL)	102.67 ± 47.75	95.24 ± 35.09	0.54	97.47 ± 46.49	92 ± 38.23	0.43	0.65
ALT (U/L)	20.26 ± 11.58	33.87 ± 70.54	**0.04**	19.66 ± 12.38	20.57 ± 10.44	0.65	0.19
AST (U/L)	35.32 ± 10.17	41.56 ± 56.84	0.28	36.22 ± 9.27	35.12 ± 12.86	0.62	0.43
Albumin (mg/dL)	4.29 ± 0.53	4.21 ± 0.52	0.53	4.23 ± 0.64	4.22 ± 0.61	0.93	0.92
LDL (mg/dL)	68.39 ± 30.60	77.15 ± 29.45	0.07	70.23 ± 38.40	68.97 ± 30.40	0.85	0.17
HDL (mg/dL)	45.86 ± 17.83	41.55 ± 12.10	0.61	43.78 ± 16.89	42.65 ± 15.76	0.73	0.69
Cholesterol (mg/dL)	136.54 ± 40.23	140.08 ± 35.58	0.75	148.05 ± 43.91	149.60 ± 5.86	0.81	0.06
Triglycerides (mg/dL)	122.54 ± 65.59	118.17 ± 55.90	0.37	151.10 ± 94.44	143.30 ± 23.20	0.57	**0.004**
C-reactive protein (mg/dL)	3.70 ± 2.60	3.55 ± 2.50	0.76	3.38 ± 2.80	3.76 ± 2.34	0.46	**0.66**

TSAT: transferrin saturation; TBARS: thiobarbituric acid reactive substances; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
The significance of bold values is $p < 0.05$.
Wilcoxon signed-rank test. *p value. **Intergroup p value.

Patients	Basal	2Hrs	4Hrs	6Hrs	24Hrs	26Hrs	48Hrs
1	10.3	5.38	10.84	9.99	7.31	ND	5.03
2	ND	3.11	3.56	ND	14.91	4.04	23.78
3	ND	2.67	2.67	ND	13.63	18.82	19.12
4	12.86	14.86	3.4	8.49	13.44	8.24	12.42

Fig. 2 – Plasma levels of deferasirox in four patients by HPLC. Mann–Whitney U test was used, with *p* < 0.05 considered significant. ND: not determined.

Discussion

There is currently strong evidence for the benefit of intravenous iron therapy in the treatment of anemia in patients with chronic kidney disease.[35] However, on the other hand, we know that iron accumulation leads to adverse effects with increased ferritin levels, increased risk of infection, and increased mortality from cardiovascular events.[36,37] In our study, iron chelation in patients with a glomerular filtration rate of less than 15 mL/min and undergoing hemodialysis significantly reduces ferritin and TBARS levels, which increases the length of the telomeres. We found significant differences at the end of the treatment when comparing serum ferritin levels, and the response in hemoglobin and hematocrit between the two groups, observing significant differences and higher levels in the group treated with deferasirox. Similarly, creatinine levels were lower after 6 months of treatment, which may indicate an improvement in dialysis efficiency by reducing inflammation and oxidative stress factors. The treatment of chronic kidney disease includes the administration of parenteral iron; unfortunately, this treatment leads to iron overload. Randomized trials in hemodialysis patients have demonstrated significantly greater increases in hemoglobin levels with IV iron when compared to oral iron, and a low rate of treatment related adverse events during these short trials.[38,39]

However, little is known about the efficacy and safety of iron chelation in patients with renal replacement therapy. Deferasirox is an oral iron chelator that is hepatically metabolized and excreted by the intestine.[29]

Marker and colleagues performed a pilot study to evaluate the pharmacokinetics and safety of deferasirox in patients with chronic renal failure undergoing hemodialysis and presenting iron overload. Deferasirox was administered at two doses of 10 mg/kg and 15 mg/kg per day for two weeks. They observed that at a dose of 10 mg/kg/day, insufficient concentrations were obtained in the blood (14.1–22.8 μmol/L) while at a dose of 15 mg/kg/day, the observed concentration was higher (40–50 μmol/L) without showing clinically adverse events.[33] In our study, the dose of 15 mg/kg maintained the plasma concentration required without adverse events during treatment. The deferasirox concentration in serum was determined by HPLC, and much higher concentrations were observed (2.67–23.78 mmol/L).

Tsai et al. reported the response of deferasirox to 15 mg/kg in patients with chronic renal failure on dialysis; serum ferritin levels decreased significantly, and those who presented amounts of 3252 ng/mL continued with a maintenance dose of 10 mg/kg.[39]

Few studies have been conducted to determine the pharmacokinetics and safety of deferasirox in hemodialysis patients. Deferasirox may cause acute renal failure, and a creatinine clearance rate of <40 mL/min and serum creatinine level of >2-fold the upper limit of normal are listed as contraindications by Novartis and the Food and Drug Administration.[40] Although the pharmacokinetics of deferasirox in patients with chronic kidney disease suggests minimal risk of accumulation because its excretion by the renal route is minimal.[9] In our study, it has been shown that there is a significant increase in plasma levels when the dose is elevated from 10 mg/kg/day to 15 mg/kg/day. It has been argued that uremia is one of the reasons why deferasirox levels are increased in the plasma level, because uremia can reduce fecal excretion and enhance reabsorption at the intestinal level. In uremic rats there is a decrease in intestinal membrane transporter protein (IMTP) and related protein (MRP2). The increased bioavailability of deferasirox can be explained by a reduction in excretion through MRP2.[41]

In this investigation, the concentration of deferasirox in serum from time zero to 48 h was maintained in a range of 2.67–23.78 mmol/L. We were able to determine the concentration of deferasirox at a dose of 15 mg/kg/day from baseline pre hemodialysis, and the following concentrations during hemodialysis (at 2, 4, 6 h), at 24 h before the next deferasirox intake, and at 48 h before entering hemodialysis therapy again. During this time there were no significant adverse events. Some authors have reported complications in hematology patients caused by iron chelation treatment such as kidney damage.[42,43]

In the present study, follow-up was conducted for six months, without significant elevations in creatinine levels, and the majority of patients had liver function tests remained within the normal limits.

Previous epidemiological studies have shown that elevated iron status is associated with an increased risk of chronic conditions such as type 2 diabetes, cardiovascular disease, and mortality.[44] Furthermore, high ferritin levels have been found to be associated with shortened telomeres, a biomarker of biological aging, and chronic age-related diseases, among patients with iron overload due to disease. However, the association between body iron status and telomere length in the general population remains unknown.

In a nationally representative population of the USA, high body iron level was associated with shorter telomeres, especially in adults 65 years of age and older.[28] Cell culture experiments indicate that pro-inflammatory conditioning and high glucose have an effect on telomere shortening, with former accelerating the process.[45] Oxidative stress also induces telomere attrition,[46] with the telomere GGG sequence particularly vulnerable to damage caused by reactive oxygen species.[47] The increased oxidative stress resulting from iron overload may induce this telomere shortening. Elevated ferritin levels contribute to telomere loss in hemodialysis patients. Indeed, shorter telomere length has been associated with an increased risk of death in CKD.[48,49]

In our experience with deferasirox in patients with chronic kidney failure undergoing hemodialysis, we observed that iron chelation prevented telomere shortening, reduced ferritin levels and lipid peroxidation, and reduced oxidative stress, with an increase in telomere length at the end of iron chelation. Iron chelation therapy is an alternative that addresses new paradigms in the management of patients undergoing renal replacement therapy; this study demonstrated recovery of hemoglobin levels and improved response to erythropoietin. Deferasirox was generally well tolerated; common adverse events included nausea, vomiting, diarrhea, and abdominal pain. Further studies are needed to support iron chelation in the prevention of survival-limiting complications in patients with CKD.

Conclusion

Our findings demonstrate that iron chelation in patients undergoing hemodialysis significantly reduces ferritin levels and oxidative damage to lipids, which results in an increase in telomere length. Treatment with deferasirox during renal replacement therapy provides an alternative approach that benefits patient by addressing complications with iron overload.

Conflict of interest

The authors have no relevant conflicts of interest to disclose.

Acknowledgments

REFERENCES

1. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011–23, http://dx.doi.org/10.1056/NEJMra041809.
2. Selmeci L, Antal M, Horkay F, Merkely B, Szokodi I, Bíró L, et al. Enhanced accumulation of pericardial fluid ferritin in patients with coronary artery disease. Coron Artery Dis. 2000;11:53–6, http://dx.doi.org/10.1097/00019501-200002000-00009.
3. Fleming RE, Bacon BR. Orchestration of iron homeostasis. N Engl J Med. 2005;352:1741–4, http://dx.doi.org/10.1056/NEJMp048363.
4. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl. 1999;69:S35–43, http://dx.doi.org/10.1046/j.1523-1755.1999.055suppl.69035.x.
5. Foury F, Talibi D. Mitochondrial control of iron homeostasis. A genome wide analysis of gene expression in a yeast frataxin-deficient strain. J Biol Chem. 2001;276:7762–8, http://dx.doi.org/10.1074/jbc.m005804200.
6. Luo Y, Henle ES, Linn S. Oxidative damage to DNA constituents by iron-mediated Fenton reactions. J Biol Chem. 1996;271:21167–76, http://dx.doi.org/10.1074/jbc.271.35.21167.
7. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.
8. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016;9:260–7, http://dx.doi.org/10.1093/ckj/sfv142.
9. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol. 2012;89:87–93, http://dx.doi.org/10.1111/j.1600-0609.2012.01783.x.
10. Lynch SM, Frei B. Mechanisms of metal ion-dependent oxidation of human low density lipoprotein. J Nutr. 1996;126 Suppl.:1063S–6S, http://dx.doi.org/10.1093/jn/126.suppl_4.1063.
11. Wieland E, Parthasarathy S, Steinberg D. Peroxidase-dependent metal-independent oxidation of low-density lipoprotein in vitro: a model for in vivo oxidation? Proc Natl Acad Sci. 1993;90:5929–33, http://dx.doi.org/10.1073/pnas.90.13.5929.
12. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96:3300–7, http://dx.doi.org/10.1161/01.cir.96.10.3300.
13. Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17 Suppl. 2:25–9, http://dx.doi.org/10.1093/ndt/17.suppl_2.25.
14. Vari IS, Balkau B, Kettaneh A, André P, Tichet J, Fumeron F, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data resistance syndrome (DESIR). Diabetes Care. 2007;30:1795–801, http://dx.doi.org/10.2337/dc06-2312.
15. Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447–58, http://dx.doi.org/10.1056/NEJMoa1810742.
16. Mainous AG 3rd, Díaz VA. Relation of serum ferritin level to cardiovascular fitness among young men. Am J Cardiol. 2009;103:115–8, http://dx.doi.org/10.1016/j.amjcard.2008.08.046.
17. Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350:1193–8, http://dx.doi.org/10.1126/science.aab3389.
18. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene. 2002;21:564–79, http://dx.doi.org/10.1038/sj.onc.1205083.
19. Passos JF, Saretzki G, von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection? Nucleic Acids Res. 2007;35:7505–13, http://dx.doi.org/10.1093/nar/gkm893.
20. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393–5, http://dx.doi.org/10.1016/S0140-6736(03)12384-7.
21. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312–5, http://dx.doi.org/10.1073/pnas.0407162101.
22. Wong LS, van der Harst P, de Boer RA, Codd V, Huzen J, Samani NJ, et al. Renal dysfunction is associated with shorter telomere length in heart failure. Clin Res Cardiol. 2009;98:629–34, http://dx.doi.org/10.1007/s00392-009-0048-7.
23. Salpea KD, Humphries SE. Association of telomere length with type diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis. 2010;209:42–50, http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.070.
24. Fazzini F, Lamina C, Raschenberger J, Schultheiss UT, Kotsis F, Schonherr S, et al. Results from the German Chronic Kidney Disease (GCKD) study support association of relative telomere length with mortality in a large cohort of patients with moderate chronic kidney disease. Kidney Int. 2020;98:488–97, http://dx.doi.org/10.1016/j.kint.2020.02.034.
25. Murillo-Ortiz B, Albarran Tamayo F, Arenas Aranda D, Benítez-Bribiesca L, Malacara Hernández J, Martínez Garza S, et al. Telomere length and type 2 diabetes in males a premature aging syndrome. Aging Male. 2011;15:54–8, http://dx.doi.org/10.3109/13685538.2011.593658.
26. Gurung RL, Yiamunaa Y, Liu S, Liu JJ, Lim SC. Short leukocyte telomere length predicts albuminuria progression in individuals with type 2 diabetes. Kidney Int Rep. 2017;3:592–601, http://dx.doi.org/10.1016/j.ekir.2017.12.005.
27. Willis LP, Schnellmann RG. Telomeres and telomerase in renal health. J Am Soc Nephrol. 2011;22:39–41, http://dx.doi.org/10.1681/asn.2010060662.

28. Liu B, Sun Y, Xu G, Snetselaar LG, Ludewig G, Wallace RB, et al. Association between body iron status and leukocyte telomere length, a biomarker of biological aging, in a nationally representative sample of U.S. adults. J Acad Nutr Diet. 2019;119:617–25, http://dx.doi.org/10.1016/j.jand.2018.09.007.

29. Novartis Pharmaceuticals Corporation 2005. Exjade (deferasirox) Prescribing information [online]. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/exjade.pdf [accessed 01.02.23].

30. Steinhauser S, Heinz U, Bartholoma M, Weyhermuller T, Nick H, Hegetschweiler K. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur J Inorg Chem. 2004;21:4177–92, http://dx.doi.org/10.1002/ejic.200400363.

31. Bruin GJ, Faller T, Wiegand H, Schweitzer A, Nick H, Schneider J, et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36:2523–38, http://dx.doi.org/10.1124/dmd.108.022962.

32. Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38:808–16, http://dx.doi.org/10.1124/dmd.109.030833.

33. Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynk JK. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;19:188–93, http://dx.doi.org/10.1111/nep.12035.

34. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18, http://dx.doi.org/10.1186/1741-7015-8-18.

35. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30:187–96, http://dx.doi.org/10.1093/ndt/gfu104.

36. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–84.

37. Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs. 2016;76:741–57, http://dx.doi.org/10.1007/s40265-016-0569-0.

38. Rostoker G, Vaziri ND. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon. 2019;5:e02045, http://dx.doi.org/10.1016/j.heliyon.2019.e02045.

39. Tsai CW, Yang FJ, Huang CC, Kuo CC, Chen YM. The administration of deferasirox in an iron-overloaded dialysis patient. Hemodial Int. 2013;17:131–3, http://dx.doi.org/10.1111/j.1542-4758.2012.00704.x.

40. Hohneker JA. Exjade (deferasirox): boxed warning. In: MedWatch: the FDA safety information and adverse event reporting program. 2010. Available from: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program [accessed 06.02.23].

41. Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007;320:978–85, http://dx.doi.org/10.1124/jpet.106.112631.

42. Badeli H, Baghersalimi A, Eslami S, Saadat F, Hassanzadeh Rad A, et al. Early kidney damage markers after deferasirox treatment in patients with thalassemia major: a case–control study. Oxid Med Cell Longev. 2019;5461617, http://dx.doi.org/10.1155/2019/5461617.

43. Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25:2376–8, http://dx.doi.org/10.1093/ndt/gfq224.

44. Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P. The association of ferritin with cardiovascular and all-cause mortality in community-dwellers: the English longitudinal study of ageing. PLoS One. 2017;12:e0178994, http://dx.doi.org/10.1371/journal.pone.0178994.

45. Salpea KD, Maubaret CG, Kathagen A, et al. The effect of pro-inflammatory conditioning and/or high glucose on telomere shortening of aging fibroblasts. PLoS One. 2013;8:e73756, http://dx.doi.org/10.1371/journal.pone.0073756.

46. Ludlow AT, Spangenburg EE, Chin ER, et al. Telomeres shorten in response to oxidative stress in mouse skeletal muscle fibers. J Gerontol A Biol Sci Med Sci. 2014;69:821–30, http://dx.doi.org/10.1093/gerona/glt211.

47. Kawanishi S, Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann N Y Acad Sci. 2004;1019:278–84, http://dx.doi.org/10.1196/annals.1297.047.

48. Astrup AS, Tarnow L, Jorsal A, Lajer M, Nzietchueng R, Benetos A, et al. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia. 2010;53:45–8, http://dx.doi.org/10.1007/s00125-009-1542-1.

49. Levstek T, Trebušak Podkrajšek K. Telomere attrition in chronic kidney diseases. Antioxidants (Basel). 2023;12:579, http://dx.doi.org/10.3390/antiox12030579.